Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to 1.96%.

  • Mirum Pharmaceuticals' EBIT Margin rose 159900.0% to 1.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.86%, marking a year-over-year increase of 224000.0%. This contributed to the annual value of 26.0% for FY2024, which is 325600.0% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported EBIT Margin of 1.96% as of Q3 2025, which was up 159900.0% from 3.9% recorded in Q2 2025.
  • Mirum Pharmaceuticals' EBIT Margin's 5-year high stood at 1.96% during Q3 2025, with a 5-year trough of 1452.36% in Q4 2021.
  • Its 5-year average for EBIT Margin is 208.53%, with a median of 58.71% in 2023.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' EBIT Margin skyrocketed by 13299400bps in 2022, and later skyrocketed by 159900bps in 2025.
  • Mirum Pharmaceuticals' EBIT Margin (Quarter) stood at 1452.36% in 2021, then skyrocketed by 92bps to 122.41% in 2022, then soared by 62bps to 46.85% in 2023, then skyrocketed by 48bps to 24.36% in 2024, then skyrocketed by 108bps to 1.96% in 2025.
  • Its EBIT Margin was 1.96% in Q3 2025, compared to 3.9% in Q2 2025 and 13.61% in Q1 2025.